

# Simon A Rule

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/1886743/simon-a-rule-publications-by-citations.pdf>

**Version:** 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

122  
papers

5,005  
citations

32  
h-index

70  
g-index

126  
ext. papers

5,998  
ext. citations

5.2  
avg. IF

5.26  
L-index

#	Paper	IF	Citations
122	Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma. <i>New England Journal of Medicine</i> , <b>2013</b> , 369, 507-16	59.2	1139
121	Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 200-211	21.7	314
120	Ibrutinib versus temsirolimus in patients with relapsed or refractory mantle-cell lymphoma: an international, randomised, open-label, phase 3 study. <i>Lancet, The</i> , <b>2016</b> , 387, 770-8	4.0	293
119	Long-term follow-up of MCL patients treated with single-agent ibrutinib: updated safety and efficacy results. <i>Blood</i> , <b>2015</b> , 126, 739-45	2.2	268
118	Acalabrutinib in relapsed or refractory mantle cell lymphoma (ACE-LY-004): a single-arm, multicentre, phase 2 trial. <i>Lancet, The</i> , <b>2018</b> , 391, 659-667	4.0	231
117	A phase 1 clinical trial of the selective BTK inhibitor ONO/GS-4059 in relapsed and refractory mature B-cell malignancies. <i>Blood</i> , <b>2016</b> , 127, 411-9	2.2	195
116	Postibrutinib outcomes in patients with mantle cell lymphoma. <i>Blood</i> , <b>2016</b> , 127, 1559-63	2.2	171
115	Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials. <i>Haematologica</i> , <b>2017</b> , 102, 1796-1805	6.6	150
114	International Working Group consensus response evaluation criteria in lymphoma (RECIL 2017). <i>Annals of Oncology</i> , <b>2017</b> , 28, 1436-1447	10.3	148
113	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2017</b> , 28, iv62-iv71	10.3	134
112	Mantle cell lymphoma: evolving management strategies. <i>Blood</i> , <b>2015</b> , 125, 48-55	2.2	131
111	Newly diagnosed and relapsed mantle cell lymphoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. <i>Annals of Oncology</i> , <b>2014</b> , 25 Suppl 3, iii83-92	10.3	104
110	Lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma (MCL-002; SPRINT): a phase 2, randomised, multicentre trial. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 319-331	21.7	103
109	A Phase 2/3 Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Lenalidomide Versus Investigator's Choice in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma. <i>Clinical Cancer Research</i> , <b>2017</b> , 23, 4127-4137	12.9	98
108	Guidelines for the management of tumour lysis syndrome in adults and children with haematological malignancies on behalf of the British Committee for Standards in Haematology. <i>British Journal of Haematology</i> , <b>2015</b> , 169, 661-71	4.5	97
107	Outcome following Reduced-Intensity Allogeneic Stem Cell Transplantation (RIC AlloSCT) for relapsed and refractory mantle cell lymphoma (MCL): a study of the British Society for Blood and Marrow Transplantation. <i>Biology of Blood and Marrow Transplantation</i> , <b>2010</b> , 16, 1419-27	4.7	82
106	Outcomes in 370 patients with mantle cell lymphoma treated with ibrutinib: a pooled analysis from three open-label studies. <i>British Journal of Haematology</i> , <b>2017</b> , 179, 430-438	4.5	77

105	Updated results from the phase 3 HELIOS study of ibrutinib, bendamustine, and rituximab in relapsed chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia</i> , <b>2019</b> , 33, 969-980	10.7	70
104	Acalabrutinib monotherapy in patients with Waldenström macroglobulinemia: a single-arm, multicentre, phase 2 study. <i>Lancet Haematology</i> , <b>2020</b> , 7, e112-e121	14.6	65
103	Guidelines for the investigation and management of mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2012</b> , 159, 405-26	4.5	61
102	The EBMT/EMCL consensus project on the role of autologous and allogeneic stem cell transplantation in mantle cell lymphoma. <i>Leukemia</i> , <b>2015</b> , 29, 464-73	10.7	57
101	Ibrutinib for the treatment of relapsed/refractory mantle cell lymphoma: extended 3.5-year follow up from a pooled analysis. <i>Haematologica</i> , <b>2019</b> , 104, e211-e214	6.6	55
100	Incidence of and risk factors for major haemorrhage in patients treated with ibrutinib: An integrated analysis. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 558-569	4.5	51
99	Subcutaneous vs intravenous rituximab in patients with non-Hodgkin lymphoma: a time and motion study in the United Kingdom. <i>Journal of Medical Economics</i> , <b>2014</b> , 17, 459-68	2.4	46
98	Combination therapy with fludarabine and cyclophosphamide as salvage treatment in lymphoproliferative disorders. <i>British Journal of Haematology</i> , <b>1999</b> , 104, 612-3	4.5	43
97	Ibrutinib versus temsirolimus: 3-year follow-up of patients with previously treated mantle cell lymphoma from the phase 3, international, randomized, open-label RAY study. <i>Leukemia</i> , <b>2018</b> , 32, 1799-1803	10.7	42
96	Blastoid and pleomorphic mantle cell lymphoma: still a diagnostic and therapeutic challenge!. <i>Blood</i> , <b>2018</b> , 132, 2722-2729	2.2	40
95	Long-term follow-up of patients with CLL treated with the selective Bruton's tyrosine kinase inhibitor ONO/GS-4059. <i>Blood</i> , <b>2017</b> , 129, 2808-2810	2.2	39
94	Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development. <i>Advances in Therapy</i> , <b>2017</b> , 34, 2210-2231	4.1	39
93	Durable response with single-agent acalabrutinib in patients with relapsed or refractory mantle cell lymphoma. <i>Leukemia</i> , <b>2019</b> , 33, 2762-2766	10.7	39
92	Addition of bortezomib to standard dose chop chemotherapy improves response and survival in relapsed mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2015</b> , 168, 55-62	4.5	39
91	Phase Ib Study of Tirabrutinib in Combination with Idelalisib or Entospletinib in Previously Treated Chronic Lymphocytic Leukemia. <i>Clinical Cancer Research</i> , <b>2020</b> , 26, 2810-2818	12.9	32
90	Guidelines on the use of colony-stimulating factors in haematological malignancies. <i>British Journal of Haematology</i> , <b>2003</b> , 123, 22-33	4.5	29
89	The addition of rituximab to fludarabine and cyclophosphamide chemotherapy results in a significant improvement in overall survival in patients with newly diagnosed mantle cell lymphoma: results of a randomized UK National Cancer Research Institute trial. <i>Haematologica</i> , <b>2016</b> , 101, 235-40	6.6	21
88	A critical appraisal of ibrutinib in the treatment of mantle cell lymphoma and chronic lymphocytic leukemia. <i>Therapeutics and Clinical Risk Management</i> , <b>2015</b> , 11, 979-90	2.9	21

87	Ibrutinib, obinutuzumab, and venetoclax in relapsed and untreated patients with mantle cell lymphoma: a phase 1/2 trial. <i>Blood</i> , <b>2021</b> , 137, 877-887	2.2	21
86	Zanubrutinib for the treatment of MYD88 wild-type Waldenström macroglobulinemia: a substudy of the phase 3 ASPEN trial. <i>Blood Advances</i> , <b>2020</b> , 4, 6009-6018	7.8	20
85	Comparing Single-Agent Ibrutinib, Bendamustine Plus Rituximab (BR) and Ibrutinib Plus BR in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL): An Indirect Comparison of the RESONATE and HELIOS Trials. <i>Blood</i> , <b>2015</b> , 126, 2944-2944	2.2	20
84	Mutational Analysis of Patients with Primary Resistance to Single-Agent Ibrutinib in Relapsed or Refractory Mantle Cell Lymphoma (MCL). <i>Blood</i> , <b>2014</b> , 124, 78-78	2.2	19
83	Outcomes in first relapsed-refractory younger patients with mantle cell lymphoma: results from the MANTLE-FIRST study. <i>Leukemia</i> , <b>2021</b> , 35, 787-795	10.7	19
82	Allogeneic stem cell transplantation as part of front line therapy for Mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 184, 999-1005	4.5	18
81	Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphoma. <i>Blood Advances</i> , <b>2021</b> , 5, 2577-2585	7.8	17
80	Guideline for the management of mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 182, 46-62.5	4.5	17
79	Safety and efficacy of obinutuzumab with CHOP or bendamustine in previously untreated follicular lymphoma. <i>Haematologica</i> , <b>2017</b> , 102, 765-772	6.6	15
78	The modern approach to mantle cell lymphoma. <i>Hematological Oncology</i> , <b>2019</b> , 37 Suppl 1, 66-69	1.3	15
77	Preference for Rituximab Subcutaneous (Sc) and Intravenous (Iv) Among Patients With Cd20+ Non-Hodgkin's Lymphoma (Nhl) Completing the Rasq Measure In Randomized Phase Iii Studies Prefmab and Mabcute. <i>Value in Health</i> , <b>2014</b> , 17, A537	3.3	13
76	Ibrutinib-associated lymphocytosis corresponds to bone marrow involvement in mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2015</b> , 170, 131-4	4.5	12
75	The Bruton's Tyrosine Kinase Inhibitor PCI-32765 Is Highly Active As Single-Agent Therapy in Previously-Treated Mantle Cell Lymphoma (MCL): Preliminary Results of a Phase II Trial. <i>Blood</i> , <b>2011</b> , 118, 442-442	2.2	12
74	Health-related quality of life data from a phase 3, international, randomized, open-label, multicenter study in patients with previously treated mantle cell lymphoma treated with ibrutinib versus temsirolimus. <i>Leukemia and Lymphoma</i> , <b>2017</b> , 58, 2824-2832	1.9	11
73	How applicable is fludarabine, cyclophosphamide and rituximab to the elderly?. <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1599-610	1.9	11
72	Interim Results of an International, Multicenter, Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765), in Relapsed or Refractory Mantle Cell Lymphoma (MCL): Durable Efficacy and Tolerability with Longer Follow-up. <i>Blood</i> , <b>2012</b> , 120, 904-904	2.2	11
71	Efficacy and Safety of Single-Agent Ibrutinib in Patients with Mantle Cell Lymphoma Who Progressed after Bortezomib Therapy. <i>Blood</i> , <b>2014</b> , 124, 4471-4471	2.2	11
70	Long-term follow-up of patients with mantle cell lymphoma (MCL) treated with the selective Bruton's tyrosine kinase inhibitor tirabrutinib (GS/ONO-4059). <i>Leukemia</i> , <b>2020</b> , 34, 1458-1461	10.7	11

69	Sequence variants in patients with primary and acquired resistance to ibrutinib in the phase 3 MCL3001 (RAY) trial.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7570-7570	2.2	10
68	Ibrutinib for the treatment of mantle cell lymphoma. <i>Expert Review of Hematology</i> , <b>2014</b> , 7, 521-31	2.8	9
67	Preliminary Results of a Phase I/II Study of Weekly or Twice Weekly Bortezomib in Combination with Rituximab, in Patients with Follicular Lymphoma, Mantle Cell Lymphoma and Waldenstro mB Macroglobulinaemia.. <i>Blood</i> , <b>2007</b> , 110, 2559-2559	2.2	9
66	Final 5-year findings from the phase 3 HELIOS study of ibrutinib plus bendamustine and rituximab in patients with relapsed/refractory chronic lymphocytic leukemia/small lymphocytic lymphoma. <i>Leukemia and Lymphoma</i> , <b>2020</b> , 61, 3188-3197	1.9	9
65	Ibrutinib for mantle cell lymphoma at first relapse: a United Kingdom real-world analysis of outcomes in 211 patients. <i>British Journal of Haematology</i> , <b>2021</b> , 193, 290-298	4.5	9
64	A Phase I Study Of The Oral Btk Inhibitor ONO-4059 In Patients With Relapsed/Refractory B-Cell Lymphoma. <i>Blood</i> , <b>2013</b> , 122, 4397-4397	2.2	8
63	Prospective subgroup analyses of the randomized MCL-002 (SPRINT) study: lenalidomide versus investigator's choice in relapsed or refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2018</b> , 180, 224-235	4.5	8
62	Novel agents in mantle cell lymphoma. <i>Expert Review of Anticancer Therapy</i> , <b>2017</b> , 17, 491-506	3.5	7
61	The Bruton Tyrosine Kinase (BTK) Inhibitor ONO-4059: Promising Single Agent Activity and Well Tolerated in Patients with High Risk Chronic Lymphocytic Leukaemia (CLL). <i>Blood</i> , <b>2014</b> , 124, 3328-3328	2.2	7
60	Acalabrutinib monotherapy in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).. <i>Journal of Clinical Oncology</i> , <b>2018</b> , 36, 7547-7547	2.2	7
59	Ibrutinib for mantle cell lymphoma. <i>Future Oncology</i> , <b>2016</b> , 12, 477-91	3.6	6
58	New and emerging Bruton tyrosine kinase inhibitors for treating mantle cell lymphoma - where do they fit in?. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 749-756	2.8	6
57	The Addition of Rituximab to Fludarabine and Cyclophosphamide (FC) Improves Overall Survival in Newly Diagnosed Mantle Cell Lymphoma (MCL): Results of the Randomised UK National Cancer Research Institute (NCRI) Trial. <i>Blood</i> , <b>2011</b> , 118, 440-440	2.2	6
56	Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA7005-LBA7005	2.2	6
55	40% of Females with Mantle Cell Lymphoma Are Managed with Initial Observation: Results from the MCL Biobank Observational Study. <i>Blood</i> , <b>2019</b> , 134, 2821-2821	2.2	5
54	Effectiveness of Lenalidomide in Patients with Mantle Cell Lymphoma Who Relapsed/Progressed after or Were Refractory/Intolerant to Ibrutinib: The MCL-004 Study. <i>Blood</i> , <b>2016</b> , 128, 1786-1786	2.2	5
53	The Bruton tyrosine kinase (BTK) inhibitor ONO-4059: Single-agent activity in patients with relapsed and refractory non-GCB-DLBCL.. <i>Journal of Clinical Oncology</i> , <b>2014</b> , 32, 8553-8553	2.2	5
52	Bortezomib-based chemotherapy in mantle cell lymphoma. <i>Lancet Oncology, The</i> , <b>2018</b> , 19, 1419-1421	21.7	5

51	Subcutaneous rituximab can be safely administered without pre-medication. <i>British Journal of Haematology</i> , <b>2018</b> , 181, 836-837	4.5	4
50	IBRUTINIB VS TEMSIROLIMUS: THREE-YEAR FOLLOW-UP OF PATIENTS WITH PREVIOUSLY TREATED MANTLE CELL LYMPHOMA FROM THE PHASE 3, INTERNATIONAL, RANDOMIZED, OPEN-LABEL RAY STUDY. <i>Hematological Oncology</i> , <b>2017</b> , 35, 143-144	1.3	4
49	A Phase 3 Trial Comparing Bortezomib Plus Rituximab with Rituximab Alone In Patients with Relapsed, Rituximab-Naive or -Sensitive, Follicular Lymphoma. <i>Blood</i> , <b>2010</b> , 116, 857-857	2.2	4
48	Obinutuzumab (GA101) in Combination with Cyclophosphamide, Doxorubicin, Vincristine and Prednisone (CHOP) or Bendamustine in Patients with Previously Untreated Follicular Lymphoma (FL): Results of the Phase Ib GAUDI Study (BO21000). <i>Blood</i> , <b>2012</b> , 120, 3686-3686	2.2	4
47	Low Rates of CNS Relapse in High Risk DLBCL Patients Treated with R-CODOX-M and R-IVAC: Results from a Phase 2 UK NCRI/Bloodwise Trial. <i>Blood</i> , <b>2016</b> , 128, 1855-1855	2.2	4
46	Ibrutinib (I) plus bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): a 2-year follow-up of the HELIOS study.. <i>Journal of Clinical Oncology</i> , <b>2016</b> , 34, 7525-7525	2.2	4
45	Phase 1b study of tirabrutinib in combination with idelalisib or entospletinib in previously treated B-cell lymphoma. <i>Leukemia</i> , <b>2021</b> , 35, 2108-2113	10.7	4
44	Pooled analysis of safety data from clinical trials evaluating acalabrutinib monotherapy in mature B-cell malignancies. <i>Leukemia</i> , <b>2021</b> , 35, 3201-3211	10.7	4
43	NCRI PETREA TRIAL: A PHASE 3 EVALUATION OF PET-GUIDED, RESPONSE-ADAPTED THERAPY IN PATIENTS WITH PREVIOUSLY UNTREATED, ADVANCED-STAGE, HIGH-TUMOUR-BURDEN FOLLICULAR LYMPHOMA. <i>Hematological Oncology</i> , <b>2019</b> , 37, 67-68	1.3	4
42	Molecular signatures for CCN1, p21 and p27 in progressive mantle cell lymphoma. <i>Journal of Cell Communication and Signaling</i> , <b>2019</b> , 13, 421-434	5.2	4
41	Identification of Patient Subgroups Demonstrating Longer Progression-Free Survival (PFS) Benefit with Bortezomib-Rituximab Versus Rituximab in Patients with Relapsed or Refractory Follicular Lymphoma (FL): Biomarker Analyses of the Phase 3 LYM3001 Study. <i>Blood</i> , <b>2011</b> , 118, 265-265	2.2	3
40	Obinutuzumab (GA101) in Combination with CHOP (Cyclophosphamide, Doxorubicin, Vincristine and Prednisone) or Bendamustine for the First-Line Treatment of Follicular Non-Hodgkin Lymphoma: Final Results from the Maintenance Phase of the Phase Ib GAUDI Study. <i>Blood</i> , <b>2014</b> , 124, 1713-1713	2.2	3
39	Frontline therapy and role of high-dose consolidation in mantle cell lymphoma. <i>Hematology American Society of Hematology Education Program</i> , <b>2016</b> , 2016, 419-424	3.1	3
38	Systemic Exposure of Rituximab Increased by Ibrutinib: Pharmacokinetic Results and Modeling Based on the HELIOS Trial. <i>Pharmaceutical Research</i> , <b>2019</b> , 36, 93	4.5	2
37	OUTCOMES IN FIRST RELAPSED-REFRACTORY YOUNGER PATIENTS WITH MANTLE CELL LYMPHOMA: RESULTS FROM THE MANTLE-FIRST STUDY. <i>Hematological Oncology</i> , <b>2019</b> , 37, 46-47	1.3	2
36	A Randomized Comparison Of Maintenance Therapy With Subcutaneous Rituximab For 2 Years Versus Until Progression In Patients With Indolent Non-Hodgkin Lymphoma: Interim Safety Data From The Mabcute Study. <i>Blood</i> , <b>2013</b> , 122, 3052-3052	2.2	2
35	Insights into the Management of Adverse Events in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma: Experience from the Phase 3 HELIOS Study of Ibrutinib Combined with Bendamustine/Rituximab. <i>Blood</i> , <b>2015</b> , 126, 2936-2936	2.2	2
34	Ibrutinib Vs Temsirolimus: Results from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL). <i>Blood</i> , <b>2015</b> , 126, 469-469	2.2	2

33	Phase I/II, first in human trial of the Bruton's tyrosine kinase inhibitor (BTKi) M7583 in patients with B cell malignancies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, e14101-e14101	2.2	2
32	A phase 1, open-label, multicenter, non-randomized study to assess the safety, tolerability, pharmacokinetics, and preliminary antitumor activity of AZD4573, a potent and selective CDK9 inhibitor, in subjects with relapsed or refractory hematological malignancies.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, 232-233	2.2	2
31	The 5-year follow-up of a real-world observational study of patients in the United Kingdom and Ireland receiving ibrutinib for relapsed/refractory mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2021</b> , 192, 1035-1038	4.5	2
30	What is the optimal initial management of the younger mantle cell lymphoma patient?. <i>Best Practice and Research in Clinical Haematology</i> , <b>2018</b> , 31, 90-98	4.2	2
29	The use of Bruton's tyrosine kinase inhibition as a bridging strategy to successful allogeneic stem cell transplant in relapsed mantle cell lymphoma. <i>Leukemia and Lymphoma</i> , <b>2016</b> , 57, 461-462	1.9	1
28	A new standard of care for mantle cell lymphoma?. <i>Lancet Oncology, The</i> , <b>2016</b> , 17, 5-6	21.7	1
27	IBRUTINIB INCREASES THE SYSTEMIC EXPOSURE OF RITUXIMAB: PHARMACOKINETIC RESULTS FROM THE HELIOS TRIAL. <i>Hematological Oncology</i> , <b>2017</b> , 35, 232-233	1.3	1
26	The EBMT Lymphoma Working Party-European Mantle Cell Lymphoma Network Consensus Project On The Role Of Autologous and Allogeneic Stem Cell Transplantation In Mantle Cell Lymphoma: Recommendations Applying The Delphi Procedure. <i>Blood</i> , <b>2013</b> , 122, 3405-3405	2.2	1
25	Rituximab and CODOX-M / IVAC Without Stem Cell Transplantation For Poor Risk Diffuse Large B Cell Lymphoma (IPI3-5) and Burkitts Lymphoma Is Feasible and Gives a High Response Rate: Preliminary Results Of a Phase 2 UK National Cancer Research Institute Trial. <i>Blood</i> , <b>2013</b> , 122, 4348-4348	2.2	1
24	Subgroup analysis of the phase II randomized MCL-002 (SPRINT) study of lenalidomide vs investigator's choice in relapsed/refractory mantle cell lymphoma.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, 8547-8547	2.2	1
23	A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL).. <i>Journal of Clinical Oncology</i> , <b>2013</b> , 31, TPS8613-TPS8613	2.2	1
22	What Causes Bruton Tyrosine Kinase Inhibitor Resistance in Mantle Cell Lymphoma and How Should We Treat Such Patients?. <i>Hematology/Oncology Clinics of North America</i> , <b>2020</b> , 34, 923-939	3.1	1
21	Advances in Classification and Treatment of Non-Hodgkin Lymphoma: Mantle Cell. <i>Cancer Journal (Sudbury, Mass)</i> , <b>2020</b> , 26, 348-356	2.2	1
20	LONGITUDINAL ANALYSES OF DIAGNOSTIC-RELAPSE BIOPSIES OF DIFFUSE LARGE B CELL LYMPHOMA SUGGEST THAT RELAPSE IS MEDIATED BY DISTINCT MECHANISMS IN ABC AND GCB LYMPHOMA. <i>Hematological Oncology</i> , <b>2019</b> , 37, 142-143	1.3	1
19	IBRUTINIB COMPARED TO STANDARD CHEMOTHERAPY FOR CENTRAL NERVOUS SYSTEM RECURRENCE OF MANTLE CELL LYMPHOMA. <i>Hematological Oncology</i> , <b>2019</b> , 37, 244-245	1.3	1
18	Receiving treatment at a specialist centre confers an overall survival benefit for patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , <b>2019</b> , 185, 1002-1004	4.5	1
17	Velcade combinations in mantle cell lymphoma: are we learning anything?. <i>Leukemia and Lymphoma</i> , <b>2011</b> , 52, 545-7	1.9	0
16	Phase I, first-in-human trial of Bruton's tyrosine kinase inhibitor M7583 in patients with B-cell malignancies. <i>Leukemia and Lymphoma</i> , <b>2021</b> , 62, 2392-2399	1.9	0

15	Response to the letter from Gozzetti et al. entitled: "Oral low-dose fludarabine and cyclophosphamide with rituximab as initial treatment for elderly patients with chronic lymphoproliferative disorders". <i>Leukemia and Lymphoma</i> , <b>2015</b> , 56, 1918	1.9
14	Does maintenance therapy have a role in mantle cell lymphoma treatment?. <i>Expert Review of Hematology</i> , <b>2018</b> , 11, 285-292	2.8
13	Can we improve on ibrutinib in mantle cell lymphoma?. <i>Lancet Haematology</i> , <b>2018</b> , 5, e98-e99	14.6
12	Management perspective for mantle cell lymphoma. <i>International Journal of Hematologic Oncology</i> , <b>2014</b> , 3, 31-40	1
11	Mantle-cell lymphoma in the elderly: is it time to CHOP and change?. <i>Leukemia and Lymphoma</i> , <b>2012</b> , 53, 1855-6	1.9
10	Managing cancer-related skeletal events with bisphosphonates. <i>British Journal of Hospital Medicine</i> , <b>2004</b> , 65, 355-60	
9	Ibrutinib combined with bendamustine and rituximab (BR) in previously treated chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): First results from a randomized, double-blind, placebo-controlled, phase III study.. <i>Journal of Clinical Oncology</i> , <b>2015</b> , 33, LBA7005-LBA7005	2.2
8	Improvement of Quality of Response with Ibrutinib Plus Bendamustine/Rituximab Vs Placebo Plus Bendamustine/Rituximab for Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL). <i>Blood</i> , <b>2015</b> , 126, 2938-2938	2.2
7	Lymphoma Symptoms: Data from a Phase 3, International, Randomized, Open-Label, Multicenter Study in Patients with Previously Treated Mantle Cell Lymphoma (MCL) Treated with Ibrutinib Vs. Temsirolimus. <i>Blood</i> , <b>2015</b> , 126, 1542-1542	2.2
6	Systemic Exposure of Rituximab Increased By Ibrutinib: Pharmacokinetic Results from the Helios Trial. <i>Blood</i> , <b>2016</b> , 128, 4403-4403	2.2
5	Outcomes Following Lenalidomide for Relapsed/Refractory Mantle Cell Lymphoma Patients at Risk of Bleeding Events Because of Multiple Comorbidities or Treatment: A Post-Hoc Subgroup Analysis of the SPRINT (MCL-002) Trial. <i>Blood</i> , <b>2016</b> , 128, 2978-2978	2.2
4	Phase I/II study of durvalumab (antiPD-L1 antibody) as monotherapy and in combination in patients with lymphoma or chronic lymphocytic leukemia.. <i>Journal of Clinical Oncology</i> , <b>2017</b> , 35, TPS7574-TPS7574	2.2
3	Effect of the Cytochrome P450 3A4 Inducers, Rifampicin and Dexamethasone, on the Pharmacokinetic, Pharmacodynamic and Safety Profile of Bortezomib In Patients with Multiple Myeloma (MM) and Non-Hodgkin's Lymphoma (NHL). <i>Blood</i> , <b>2010</b> , 116, 3983-3983	2.2
2	Evolving concepts in tumour lysis syndrome management - response to Ayed et al. <i>British Journal of Haematology</i> , <b>2016</b> , 173, 486-7	4.5
1	Mantle Cell Lymphoma. <i>Hematologic Malignancies</i> , <b>2021</b> , 163-178	0